<DOC>
	<DOC>NCT02177461</DOC>
	<brief_summary>Study to assess the efficacy and tolerability of Telmisartan 40-80 mg once daily compared with enalapril 10-20 mg once daily in elderly patients with arterial hypertension.</brief_summary>
	<brief_title>Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Age ≥ 65 years Sitting systolic blood pressure (SBP) ≥ 160 mmHg and any diastolic blood pressure (DBP) (safety maximum of sitting DBP 110 mmHg), measured by manual cuff sphygmomanometer at the end of the washout period Written informed consent Secondary hypertension Malignant hypertension (retinal haemorrhage, exudates or papillary oedema) Clinically significant sodium depletion as defined by serum sodium level &lt; 130 mEq/L, clinically significant hyperkaliemia as defined by serum potassium level &gt; 5.5 mEq/L, clinically significant hypokaliemia as defined by serum potassium level &lt; 3.0 mEq/L Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm Heart rate &lt; 50 bpm Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF IIIIV) Angina pectoris or myocardial infarction Cardiac surgery within the past 3 months prior to start the washout period Stroke within the past 6 months prior to start the washout period Renal insufficiency defined as creatininaemia &gt; 2mg/dl Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post renal transplant Liver insufficiency, defined as bilirubinaemia &gt; 2mg/dl and AST (aspartate aminotransferase) or ALT (alanineaminotransferase) &gt; twice the upper normal range Clinically significant metabolic and endocrine disease Autoimmune disease Previous history of angioedema Body mass index &gt; 30kg/m2 Arm circumference &gt; 32 cm Any condition that may be likely to compromise the trial (alcohol or drug abuse, disability illness, etc.) Concomitant therapy with antihypertensive drugs nonpermitted by protocol, or present use of tricyclic antidepressant, corticosteroids or drugs known to affect blood pressure Investigational drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial Sensitivity, significant adverse reaction or contraindications to the study drugs (telmisartan, enalapril, clonidine TTS) Predictable lack of patient cooperation</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>